As the possibilities for cannabis-based treatments continue to make headlines in the medical world, One World Cannabis, a medical-cannabis research company, has announced that the initial results of its landmark study on treating multiple myeloma with cannabis-based solutions were extremely promising. After a series of tests using cannabis-based treatments, researchers were able to eradicate 60 percent of multiple myeloma cells.
The disease is one of the most deadly hematologic cancers and individuals diagnosed with the disease often have about a 50 percent survival rate.
OWC Pharmaceutical Research Corp. on Wednesday announced that its wholly owned subsidiary, One World Cannabis Ltd., an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, has received the first basic science study (lab) results on the effect of several combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cell line RPMI8226.
Based on the results, One World Cannabis will submit the clinical trial protocol to the IRB (Helsinki committee). The company expects to receive institutional review board approval for the study within 6-9 weeks.
The OWC multiple myeloma study was done by three repetitive tests on the effect of cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50 percent concentration). The results present more than 60 percent malignant cell death. More results of pure THC and CBD are under further analysis.